Gan & Lee Pharmaceuticals Co Ltd (603087) - Net Assets
Based on the latest financial reports, Gan & Lee Pharmaceuticals Co Ltd (603087) has net assets worth CN¥11.83 Billion CNY (≈ $1.73 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥12.68 Billion ≈ $1.86 Billion USD) and total liabilities (CN¥851.65 Million ≈ $124.62 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Gan & Lee Pharmaceuticals Co Ltd annual equity growth to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥11.83 Billion |
| % of Total Assets | 93.28% |
| Annual Growth Rate | 25.9% |
| 5-Year Change | 14.37% |
| 10-Year Change | 415.48% |
| Growth Volatility | 21.15 |
Gan & Lee Pharmaceuticals Co Ltd - Net Assets Trend (2013–2025)
This chart illustrates how Gan & Lee Pharmaceuticals Co Ltd's net assets have evolved over time, based on quarterly financial data. Check Gan & Lee Pharmaceuticals Co Ltd (603087) strategic asset index to assess the company's strategic physical and investment asset allocation.
Annual Net Assets for Gan & Lee Pharmaceuticals Co Ltd (2013–2025)
The table below shows the annual net assets of Gan & Lee Pharmaceuticals Co Ltd from 2013 to 2025. For live market cap and overall valuation, see how much is Gan & Lee Pharmaceuticals Co Ltd worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥11.63 Billion ≈ $1.70 Billion |
+5.19% |
| 2024-12-31 | CN¥11.05 Billion ≈ $1.62 Billion |
+2.90% |
| 2023-12-31 | CN¥10.74 Billion ≈ $1.57 Billion |
+12.07% |
| 2022-12-31 | CN¥9.59 Billion ≈ $1.40 Billion |
-5.72% |
| 2021-12-31 | CN¥10.17 Billion ≈ $1.49 Billion |
+13.75% |
| 2020-12-31 | CN¥8.94 Billion ≈ $1.31 Billion |
+63.38% |
| 2019-12-31 | CN¥5.47 Billion ≈ $800.55 Million |
+28.10% |
| 2018-12-31 | CN¥4.27 Billion ≈ $624.94 Million |
+28.04% |
| 2017-12-31 | CN¥3.34 Billion ≈ $488.07 Million |
+47.85% |
| 2016-12-31 | CN¥2.26 Billion ≈ $330.10 Million |
+51.83% |
| 2015-12-31 | CN¥1.49 Billion ≈ $217.41 Million |
+43.10% |
| 2014-12-31 | CN¥1.04 Billion ≈ $151.93 Million |
+41.60% |
| 2013-12-31 | CN¥733.22 Million ≈ $107.29 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Gan & Lee Pharmaceuticals Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2654.2% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥7.31 Billion | 62.82% |
| Other Components | CN¥4.32 Billion | 37.18% |
| Total Equity | CN¥11.63 Billion | 100.00% |
Gan & Lee Pharmaceuticals Co Ltd Competitors by Market Cap
The table below lists competitors of Gan & Lee Pharmaceuticals Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Valaris Ltd
NYSE:VAL
|
$5.92 Billion |
|
Genesis Minerals Ltd
AU:GMD
|
$5.92 Billion |
|
Reinet Investments S.C.A
AS:REINA
|
$5.93 Billion |
|
Landstar System Inc
NASDAQ:LSTR
|
$5.93 Billion |
|
Immunovant Inc
NASDAQ:IMVT
|
$5.91 Billion |
|
ZALANDO SE UNSP.ADR /2
F:ZAL1
|
$5.91 Billion |
|
Red Avenue New Materials Group Co Ltd
SHG:603650
|
$5.91 Billion |
|
Xinjiang Daqo New Energy Co Ltd
SHG:688303
|
$5.90 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Gan & Lee Pharmaceuticals Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 11,054,470,662 to 11,628,469,164, a change of 573,998,502 (5.2%).
- Net income of 1,143,583,603 contributed positively to equity growth.
- Dividend payments of 597,525,269 reduced retained earnings.
- Other comprehensive income decreased equity by 4,036,954.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥1.14 Billion | +9.83% |
| Dividends Paid | CN¥597.53 Million | -5.14% |
| Other Comprehensive Income | CN¥-4.04 Million | -0.03% |
| Other Changes | CN¥31.98 Million | +0.27% |
| Total Change | CN¥- | 5.19% |
Book Value vs Market Value Analysis
This analysis compares Gan & Lee Pharmaceuticals Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.48x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 43.39x to 3.48x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥1.56 | CN¥67.70 | x |
| 2014-12-31 | CN¥2.02 | CN¥67.70 | x |
| 2015-12-31 | CN¥2.92 | CN¥67.70 | x |
| 2016-12-31 | CN¥4.44 | CN¥67.70 | x |
| 2017-12-31 | CN¥6.60 | CN¥67.70 | x |
| 2018-12-31 | CN¥8.46 | CN¥67.70 | x |
| 2019-12-31 | CN¥9.74 | CN¥67.70 | x |
| 2020-12-31 | CN¥15.92 | CN¥67.70 | x |
| 2021-12-31 | CN¥18.11 | CN¥67.70 | x |
| 2022-12-31 | CN¥17.07 | CN¥67.70 | x |
| 2023-12-31 | CN¥18.95 | CN¥67.70 | x |
| 2024-12-31 | CN¥18.70 | CN¥67.70 | x |
| 2025-12-31 | CN¥19.47 | CN¥67.70 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Gan & Lee Pharmaceuticals Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 9.83%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 28.22%
- • Asset Turnover: 0.32x
- • Equity Multiplier: 1.09x
- Recent ROE (9.83%) is below the historical average (18.40%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 27.92% | 29.56% | 0.83x | 1.14x | CN¥131.41 Million |
| 2014 | 29.39% | 32.94% | 0.77x | 1.16x | CN¥201.38 Million |
| 2015 | 30.11% | 36.68% | 0.67x | 1.22x | CN¥298.83 Million |
| 2016 | 34.11% | 43.45% | 0.68x | 1.15x | CN¥544.03 Million |
| 2017 | 32.38% | 45.56% | 0.63x | 1.12x | CN¥746.41 Million |
| 2018 | 21.87% | 39.12% | 0.51x | 1.10x | CN¥506.88 Million |
| 2019 | 21.34% | 40.32% | 0.48x | 1.10x | CN¥620.18 Million |
| 2020 | 13.77% | 36.61% | 0.35x | 1.06x | CN¥336.86 Million |
| 2021 | 14.29% | 40.22% | 0.33x | 1.07x | CN¥436.02 Million |
| 2022 | -4.59% | -25.67% | 0.16x | 1.11x | CN¥-1.40 Billion |
| 2023 | 3.17% | 13.04% | 0.22x | 1.09x | CN¥-734.18 Million |
| 2024 | 5.56% | 20.18% | 0.25x | 1.09x | CN¥-490.78 Million |
| 2025 | 9.83% | 28.22% | 0.32x | 1.09x | CN¥-19.26 Million |
Industry Comparison
This section compares Gan & Lee Pharmaceuticals Co Ltd's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,457,434,339
- Average return on equity (ROE) among peers: 6.14%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Gan & Lee Pharmaceuticals Co Ltd (603087) | CN¥11.83 Billion | 27.92% | 0.07x | $5.92 Billion |
| Beijing Centergate Technologies Holding Co Ltd (000931) | $2.13 Billion | 7.47% | 2.10x | $465.07 Million |
| Blue Sail Medical Co Ltd (002382) | $9.82 Billion | 17.91% | 0.74x | $894.97 Million |
| Andon Health Co Ltd (002432) | $1.37 Billion | -12.12% | 0.53x | $4.92 Billion |
| Allmed Medical Products Co Ltd Class A (002950) | $1.10 Billion | 21.28% | 1.07x | $888.67 Million |
| Guangzhou Improve Med Instrument (300030) | $762.33 Million | -8.29% | 0.87x | $311.73 Million |
| QITIAN Technology Group Co Ltd (300061) | $2.55 Billion | 2.05% | 0.41x | $649.95 Million |
| Shanghai Tofflon Science Tech (300171) | $3.00 Billion | 7.82% | 0.40x | $1.47 Billion |
| Truking Technology Ltd (300358) | $2.32 Billion | 6.92% | 0.71x | $960.60 Million |
| Jiangxi Sanxin Medtec Co Ltd (300453) | $978.79 Million | 15.93% | 0.44x | $741.82 Million |
| Shenyang Xingqi Pharmaceutical Co Ltd (300573) | $554.58 Million | 2.46% | 0.28x | $1.55 Billion |
About Gan & Lee Pharmaceuticals Co Ltd
Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the research, development, production, and sale of insulin analog active pharmaceutical ingredients (APIs) and injections in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin… Read more